Formulation with improved bioavailability

Amorphous TML-6 formulations with excipients improve curcumin's solubility and bioavailability, addressing its therapeutic limitations and enhancing treatment efficacy for neurodegenerative diseases.

JP2024161001APending Publication Date: 2024-11-15MERRY LIFE BIOMEDICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024074672
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-05-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Curcumin's low bioavailability and rapid metabolism hinder its therapeutic development for human diseases, particularly neurodegenerative diseases.

Method used

Formulations containing amorphous TML-6, a curcumin derivative, with improved solubility and bioavailability, characterized by specific DSC and XRPD patterns, and combined with excipients like polymethacrylate-based copolymers and cellulose derivatives, enhance absorption and efficacy.

Benefits of technology

The formulations demonstrate enhanced solubility and bioavailability, leading to improved therapeutic effects in treating neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161001000014
    Figure 2024161001000014
  • Figure 2024161001000015
    Figure 2024161001000015
  • Figure 2024161001000016
    Figure 2024161001000016
Patent Text Reader

Abstract

To provide an oral formulation comprising a curcumin derivative, with an improved solubility, bioavailability and / or PK profile.SOLUTION: The present invention relates to a formulation comprising TML-6 or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof in an amorphous form, and one or more excipients.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 500,094, filed May 4, 2023, which is incorporated by reference in its entirety.

[0002] FIELD OF THEINVENTION The invention of the present disclosure relates to formulations comprising curcumin derivatives. More particularly, the present disclosure relates to oral formulations comprising curcumin derivatives having improved solubility, bioavailability and / or PK profile. [Background technology]

[0003] Curcumin is the main component of Curcumin longa, commonly known as turmeric, a perennial plant belonging to the ginger family that grows naturally in India and other parts of Asia. Curcumin is effective against a wide variety of diseases, including cancer, cardiovascular disease, obesity, liver disease, inflammatory diseases, and aging. Although the beneficial effects of curcumin have been suggested by a series of epidemiological surveys, animal experiments, and cell line studies, the low bioavailability and rapid metabolism of curcumin have hindered its therapeutic development for human diseases [Jager R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM: Comparative absorption of curcumin formulations. Nutr J 2014, 13:11]. Summary of the Invention

[0004] The present disclosure demonstrates that formulations comprising curcumin derivatives with improved solubility and bioavailability and / or PK profiles treat and / or prevent neurodegenerative diseases.

[0005] The present disclosure relates to an amorphous form of TML-6, [ka] or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and one or more excipients.

[0006] In one embodiment, the formulation is characterized by a differential scanning calorimetry thermogram that does not contain a sharp endothermic peak.

[0007] In one embodiment, the formulation is characterized by a DSC thermogram that does not contain an endothermic peak corresponding to crystalline TML-6.

[0008] In one embodiment, the formulation is characterized by a DSC thermogram that includes a broad endothermic peak at about 50°C to about 90°C.

[0009] In one embodiment, the formulation is characterized by an X-ray powder diffraction (XRPD) pattern that is essentially continuous (without sharp, narrow diffraction peaks).

[0010] 6. The formulation of claim 5, characterized by an XRPD pattern that does not include degree 2θ-reflections (±0.2° 2θ) at one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°.

[0011] The present disclosure relates to a composition comprising about 20% (w / w) to 90% (w / w) TML-6, [ka] or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and from about 10% (w / w) to about 80% (w / w) of one or more excipients.

[0012] In one embodiment, the TML-6, or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, is in an amorphous form.

[0013] In one embodiment, the formulation comprises about 70% (w / w) to 90% (w / w) TML-6, or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and about 10% (w / w) to about 30% (w / w) of one or more excipients.

[0014] In one embodiment, the one or more excipients include an enteric polymer.

[0015] In one embodiment, the one or more excipients include at least one of a polymethacrylate-based copolymer, a poly(methacrylic acid)-based copolymer, a poloxamer, and a cellulosic excipient.

[0016] In one embodiment, the ratio of polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer to cellulosic excipient ranges from about 1:5 to about 5:1.

[0017] In one embodiment, the amount of polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer ranges from about 10% to about 70% (w / w) and the amount of cellulose derivative excipient ranges from about 10% to about 70% (w / w).

[0018] In one embodiment, the polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer is selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, ethyl acrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:2, polymers of methyl acrylate, methyl methacrylate, and methacrylic acid, poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1, poly(acrylic acid Ethyl, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.1, poly(ethyl acrylate , methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate) 2:1 with 0.7% (PEG stearyl ether), poly(ethyl acrylate, methyl methacrylate) 2:1 with 1.5% (nonoxynol) and poly(ethyl acrylate, methyl methacrylate) 2:1 with 1.5% (nonoxynol) and combinations thereof.

[0019] In one embodiment, the cellulose derivative excipient is selected from the group consisting of cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, cellulose ester derivatives, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropylmethylcellulose phthalate, microcrystalline cellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose.

[0020] In one embodiment, the formulation is in the form of a tablet, granules, capsule, or spray-dried powder.

[0021] The disclosure also provides pharmaceutical compositions comprising the formulation and one or more additional excipients.

[0022] In one embodiment, the one or more additional excipients include, but are not limited to, diluents, disintegrants, binders, lubricants, and glidants.

[0023] The present disclosure further provides a method of preventing and / or treating a neurodegenerative disease, a liver disease, cancer, a cardiovascular disease, obesity, an inflammatory disease or aging in a subject in need of treatment, comprising administering to said subject a formulation or pharmaceutical composition.

[0024] In one embodiment, the neurodegenerative disease is amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease, or prion disease. [Brief description of the drawings]

[0025] [Figure 1] FIG. 1 shows the X-ray powder diffraction (XRPD) pattern of TML-6. [Diagram 2] FIG. 2 shows the XRPD pattern of TML-6 formulation E13. [Diagram 3] FIG. 3 shows the DSC thermograms of TML-6 and TML-6 formulations E14 to E17. [Figure 4] FIG. 4 shows the DSC thermograms of TML-6 and TML-6 formulation E04. [Diagram 5] FIG. 5 shows the DSC thermograms of TML-6 and TML-6 formulations E10 and E12. [Figure 6] FIG. 6 shows the plasma concentration-time profiles (mean) of TML-6 in rats following a single dose of TML-6 and TML-6 formulations E02, E10, E12 and E13 from 0 to 10 hours. [Figure 7] FIG. 7 shows the mean plasma concentration-time profiles of TML-6 in dogs following a single dose of TML-6 and TML-6 formulations E02, E10, E12 and E13 from 0 to 25 hours. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] The present invention can be more easily understood by referring to the following detailed description of various embodiments of the present invention, examples, and chemical diagrams and tables, together with their associated descriptions.Unless otherwise specifically indicated by the claims, it should be understood that the present invention is not limited to a specific preparation method, carrier or formulation, or a specific manner of formulating the compounds of the present invention into products or compositions intended for topical, oral or parenteral administration, because such things can of course vary, as those skilled in the relevant art will fully appreciate.It should also be understood that the terms used herein are only intended to describe specific embodiments, and are not intended to be limiting.

[0027] In this application, terms such as "a," "an," and "the" are not intended to refer only to a singular entity, but include a general class for which a specific example may be used for illustration. The terms "a," "an," and "the" are used interchangeably with the term "at least one." The phrases "at least one of" and "including at least one of," followed by a list, refer to any one of the items in the list and any combination of two or more items in the list. All numerical ranges include their endpoints and non-integer values ​​between the endpoints unless otherwise stated.

[0028] The term "subject" as used herein means any animal, preferably a mammal, more preferably a human. Examples of subjects include humans, non-human primates, rodents, guinea pigs, rabbits, sheep, pigs, goats, cows, horses, dogs and cats.

[0029] The terms "treating" or "treatment" as used herein mean to reverse, alleviate, inhibit the progression of, or ameliorate the disorder, disease or condition to which such term applies, or one or more symptoms of such disorder, disease or condition.

[0030] The term "polymer" refers to a molecule having a structure that includes multiple repeats of units that are actually or conceptually derived from molecules of low relative molecular mass.

[0031] The term "solvent" refers to a homogeneous liquid material, which may be a single compound or a combination of compounds, and which may or may not contain water.

[0032] The term "carrier" or "excipient" as used herein refers to any substance, not itself a therapeutic agent, used as a carrier and / or diluent and / or adjuvant, or vehicle for delivery of a therapeutic agent to a subject, or added to a formulation to improve its handling or storage characteristics, or to allow or facilitate the formulation of a dosage unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration.

[0033] As used herein, the term "pharmacologically acceptable" is defined herein to refer to compounds, materials, compositions and / or dosage forms that are suitable, within the scope of sound medical judgment, for contact with the tissues of a subject, e.g., a mammal or human, without excessive toxicity, irritant allergic response and other problem complications.

[0034] The compound TML-6 described herein is a curcumin derivative or synthetic curcumin derivative that has anti-inflammatory properties that have been implicated in multiple mechanisms in the pathogenesis of AD and shows significantly greater activity than curcumin in reducing brain Aβ levels and anti-inflammation.TML-6 can exist in the form of its pharma- ceutically acceptable salts, solvates, hydrates, or prodrugs.

[0035] In some embodiments, the present disclosure provides TML-6 in amorphous or crystalline form; [ka] or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and one or more excipients.

[0036] In some embodiments, TML-6 is in an amorphous form. Without intending to be bound by any theory, the applicant has surprisingly found that the amorphous form of TML-6 has improved solubility, dissolution and / or bioavailability. The amorphous form of TML-6 can be detected and determined by any known method, such as X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC).

[0037] For example, the formulation may be characterized by a differential scanning calorimetry thermogram that does not include a sharp endothermic peak, a DSC thermogram that does not include an endothermic peak (at about 132±5° C.) corresponding to crystalline TML-6, or a DSC thermogram that includes a broad endothermic peak (e.g., at about 50° C. to about 90° C.). In some embodiments, the broad endothermic peak may correspond to one or more excipients. In another aspect, the formulation may be characterized by an X-ray powder diffraction (XRPD) pattern that is essentially continuous (without sharp, narrow diffraction peaks), or an XRPD pattern that does not include degree 2θ-reflections (±0.2° 2θ) at one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°.

[0038] The particle size of the drug, TML-6, is controlled by drying and / or milling / sieving (non-limiting examples are described below). The particle size can also be comminuted using roller compaction and / or milling / sieving. In the present disclosure, at least 60% of the particle size distribution of TML-6, or its pharma-ceutically acceptable salts, solvates, hydrates, or prodrugs in the formulation is less than 150 μm. The particle size distribution can be measured using sieve analysis, photon correlation spectroscopy or laser diffraction (International Standard ISO 13320-1), or electronic sensing zone, light blocking, sedimentation, or microscopy, procedures well known by those skilled in the art.

[0039] One or more excipients are combined with TML-6 to prepare the formulations described herein. The formulations described herein include about 20% (w / w) to 90% (w / w) TML-6, or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and about 10% (w / w) to about 80% (w / w) of one or more excipients. In some embodiments, the formulations may include about 70% (w / w) to 90% (w / w) TML-6, or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and about 10% (w / w) to about 30% (w / w) of one or more excipients.

[0040] The one or more excipients include one or more polymethacrylate-based copolymers, poly(methacrylic acid)-based copolymers, poloxamers, and / or cellulose derivative excipients. Without intending to be bound by any theory, it is believed that these excipients can increase the dissolution of TML-6 in gastric and / or intestinal fluids, control the solid form of TML-6 (preferably in amorphous form), and / or improve the PK profile of the TML-6 formulation. Preferably, the amount of polymethacrylate-based copolymer ranges from about 10% to about 70% (w / w) and the amount of cellulose derivative excipient ranges from about 10% to about 70% (w / w). The polymethacrylate-based copolymers include poly(methyl methacrylate) (PMMA)-based copolymers. Particular embodiments of PMMA-based copolymers include, but are not limited to, neutral, cationic, and anionic forms of PMMA-based copolymers. In some embodiments, the PMMA-based copolymer may include a copolymer based on methyl methacrylate and one or more of methacrylic acid, methacrylic acid esters, and acrylic acid esters. In further embodiments, the PMMA is poly(methacrylic acid-co-methyl methacrylate). In some further embodiments, the poly(methacrylic acid-co-methyl methacrylate) includes, but is not limited to, any one of the methacrylic acid and methyl methacrylate based polymers described herein.

[0041] Specific embodiments of poly(methacrylic acid)-based copolymers include, but are not limited to, copolymers of methacrylic acid with methyl acrylate, ethyl acrylate, tert-butyl acrylate, methyl methacrylate, and N-isopropylacrylamide. In further embodiments, the poly(methacrylic acid)-based copolymer can be a methacrylic acid-methyl methacrylate copolymer (1:1) and / or a methacrylic acid-ethyl acrylate copolymer (1:1).

[0042] Specific embodiments of cellulose derivative excipients include, but are not limited to, cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, cellulose ester derivatives, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropylmethylcellulose phthalate, microcrystalline cellulose (MCC), hydroxyethylcellulose, and hydroxypropylmethylcellulose.

[0043] In some embodiments, the polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer can be selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, ethyl acrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:2, polymers of methyl acrylate, methyl methacrylate, and methacrylic acid, poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1 ... Ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2- (methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.1, poly( Poly(ethyl acrylate, methyl methacrylate) 2:1 with 0.7% (PEG stearyl ether), poly(ethyl acrylate, methyl methacrylate) 2:1 with 1.5% (nonoxynol), and poly(ethyl acrylate, methyl methacrylate) 2:1 with 1.5% (nonoxynol), and combinations thereof.

[0044] In some embodiments, the ratio of polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer to cellulosic excipient ranges from about 1:5 to about 5: 1. For example, the ratio of poly(methacrylic acid)-based copolymer to cellulosic excipient ranges from about 1:5 to about 5:1, such as 5:25, 6:24, 7:23, 8:22, 9:21, 10:20, 11:19, 12:18, 13:17, 14:16, 15:15, 16:14, 17:13, 18:12, 19:11, 20:10, 21:9, 22:8, 23:7, 24:6, or 25:5.

[0045] In some embodiments, the one or more excipients include one or more polymeric materials, such as polysorbates and / or poloxamers. Particular embodiments of polysorbates include, but are not limited to, tween 20, tween 40, tween 60, tween 80, and tween 85. Particular embodiments of poloxamers include, but are not limited to, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407. These polymeric materials can be used alone or in combination with one or more polymethacrylate-based copolymers and / or cellulosic excipients.

[0046] The formulations described herein can be prepared by ball milling, wet granulation, direct compression and dry granulation, hot melt extrusion or spray drying. In some embodiments, the formulations can be in the form of granules, spray dried powders, capsules or tablets.

[0047] The formulations described herein can be optionally combined with one or more additional excipients to form a pharmaceutical composition.In one embodiment, the pharmaceutical composition can be a tablet or a capsule.Specific embodiments of the one or more additional excipients include, but are not limited to, diluents, disintegrants, binders, lubricants, and glidants.

[0048] Lubricants are typically added to prevent the tableting material from sticking to the punches, minimize friction during tablet compression, and facilitate removal of the compressed tablet from the die. Examples of pharma- ceutically acceptable lubricants and pharma-ceutically acceptable glidants include, but are not limited to, colloidal silica, magnesium trisilicate, starch, talc, tribasic calcium phosphate, magnesium stearate, aluminum stearate, calcium stearate, magnesium carbonate, magnesium oxide, polyethylene glycol, powdered cellulose, and microcrystalline cellulose.

[0049] Binders are agents that give powder materials cohesive properties. Commonly used binders include starch and sugars, such as sucrose, glucose, dextrose and lactose. Examples of pharma-ceutically acceptable binders include, but are not limited to, starch; cellulose and its derivatives, such as microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropyl methyl cellulose; sucrose; dextrose; corn syrup; polysaccharides; and gelatin.

[0050] Diluents are added to increase the bulk weight of the mixture and thus provide a practical size for compression. Examples of pharma- ceutically acceptable fillers and pharma-ceutically acceptable diluents include, but are not limited to, powdered sugar, compressible sugar, dextrates, dextrin, dextrose, lactose, mannitol, microcrystalline cellulose, powdered cellulose, sorbitol, sucrose, and talc.

[0051] Disintegrants are often included to ensure that tablets have an acceptable disintegration rate.Typical disintegrants include starch derivatives and salts of carboxymethylcellulose.Examples of pharmaceutically acceptable disintegrants include, but are not limited to, starch; clay; cellulose; alginate; gum; cross-linked polymers such as cross-linked polyvinylpyrrolidone (VPV), cross-linked calcium carboxymethylcellulose and cross-linked sodium carboxymethylcellulose; soybean polysaccharides; and guar gum.

[0052] Examples of glidants include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, and sodium stearyl fumarate.

[0053] Other examples of useful excipients are described in Handbook of pharmaceutical excipients, 3rd Edition, edited by AH Kibbe, published by American Pharmaceutical Association, Washington DC, ISBN: 0-917330-96-X, or Handbook of Pharmaceutical Excipients (4th Edition), edited by Raymond C Rowe - Publisher: Science and Practice.

[0054] The present disclosure also provides a method of preventing and / or treating a neurodegenerative disease, a liver disease, cancer, a cardiovascular disease, obesity, an inflammatory disease or aging in a subject in need of treatment, comprising administering to said subject a formulation or pharmaceutical composition described herein. The application of TML-6 for the treatment of these diseases has been reviewed in Min Hao, Yue Chu, Jingxuan Lei, Zhouhui Yao, Pingping Wang, Ziyan Chen, Kuilong Wang, Xiangan Sang, Xin Han, Lu Wang, Gang Cao. Pharmacological Mechanisms and Clinical Applications of Curcumin: Update. Aging and disease. 2023, 14(3): 716~749 https: / / doi.org / 10.14336 / AD.2022.1101 and Su IJ, Chang HY, Wang HC, Tsai KJ. A Curcumin Analog Exhibits Multiple Biologic Effects on the Pathogenesis of Alzheimer's Disease and Improves Behavior, Inflammation, and β-Amyloid Accumulation in a Mouse Model. Int J Mol Sci. 2020 Jul 30;21(15):5459. doi: 10.3390 / ijms21155459. PMID: 32751716; PMCID: PMC7432838. Examples of neurodegenerative diseases include, but are not limited to, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease, and prion diseases.

[0055] The formulations and pharmaceutical compositions described herein have improved solubility and bioavailability, thus providing advantageous efficacy in the prevention and / or treatment of neurodegenerative diseases. EXAMPLES

[0056] The following examples / studies are provided to aid those of ordinary skill in the art in practicing the present invention.

[0057] Preparation of the formulations of the present disclosure: Wet granulation For the formulations of Examples 1-3 (E01-E03), the ingredients listed in Table 1 were sieved and mixed to form granules, which were then dried and molded to form the formulation product. In Table 1, TPGS is an abbreviation for D-α-tocopherol polyethylene glycol-1000 succinate, and SDS is an abbreviation for sodium dodecyl sulfate (also known as SLS).

[0058] [Table 1]

[0059] Preparation of the formulations of the present disclosure: Solvent evaporation solid dispersion For formulations of Examples 4-12 (E04-E12), the ingredients listed in Table 2 were dispersed in a solvent (purified water, 95% ethanol and / or acetone) and the resulting dispersion was dried in an oven. After cooling, the dried dispersion was ground and sieved.

[0060] [Table 2]

[0061] Preparation of the formulations of the present disclosure: Spray drying The ingredients of the formulation of Example 13 (E13) are as shown in Table 1.

[0062] [Table 3]

[0063] The above ingredients were mixed and the resulting mixture was sprayed using a spray dryer, and then the spray dried powder was collected.

[0064] The formulations of Examples 14-17 were prepared using the same spray drying method and their ingredients are as shown in Table 4.

[0065] [Table 4]

[0066] X-ray powder diffraction (XRPD) studies TML-6 (unformulated) and TML-6 formulation E13 were analyzed on a zero background sample holder to present it for X-ray analysis. The XRPD pattern of TML-6 (Figure 1) showed degree 2θ-reflections (±0.2° 2θ) at 5.5°, 11.1°, 15.7°, 16.7°, 22.3°, etc., indicating a crystalline state.

[0067] The XRPD pattern of TML-6 formulation E13 (FIG. 4) was essentially continuous, without sharp, narrow diffraction peaks, indicating an amorphous morphology.

[0068] Differential scanning calorimetry (DSC) studies Samples (1-2 mg) are accurately weighed into aluminum pans, sealed, and heated from 40° C. to 160° C. with a heating ramp of 10° C. / min for DSC analysis.

[0069] The DSC thermogram of TML-6 (Figure 3) was characterized by one sharp endothermic peak at 134.25°C, corresponding to its melting point in the crystalline state.

[0070] The DSC thermograms of TML-6 formulations E14-E17 (FIG. 3) show broad peaks at about 50° C. to about 90° C. corresponding to the melting points of the (possibly shifting) excipients, and no peaks characteristic of crystalline TML-6.

[0071] The DSC melting points of TML-6 formulations E10 and E12 (FIG. 5) did not show any significant exothermic or endothermic peaks, also indicating an amorphous form.

[0072] The DSC thermogram of TML-6 formulation E04 (Figure 4) showed an endothermic peak at 132.55°C, close to the endothermic peak of TML-6 (approximately 132.85°C), indicating a crystalline state.

[0073] Dissolution test in 0.1 HCl and pH 6.8 phosphate buffer for 30 minutes The dissolution of TML-6 (API alone) and TML-6 formulations (E01-E12) was measured in a medium simulating gastric fluid for 30 minutes with the results shown in Tables 5 and 6. The dissolution of TML-6 (API alone) and TML-6 formulations (E13-E17) was measured in a medium simulating intestinal fluid for 30 minutes with the results shown in Table 6.

[0074] [Table 5]

[0075] [Table 6]

[0076] With reference to Tables 5 and 6 above, the addition of polymethacrylate-based copolymers, poly(methacrylic acid)-based copolymers, poloxamers and / or cellulose derivative excipients can effectively improve the dissolution of TML-6. Moreover, TML-6 shows improved dissolution in the amorphous form than in the crystalline form.

[0077] Pharmacokinetic (PK) studies in rats The objective of this study was to obtain the pharmacokinetic profiles of TML-6 API (unformulated, crystalline), TML-6 formulation E02 (crystalline), and TML-6 formulations E10, E12, and E13 (amorphous) through oral (PO) doses when administered to 6-8 week old male Sprague-Dawley rats (BioLASCO Taiwan Co. Ltd). Five dose study design in rats. Animals received a single dose of 25 mg / kg of TML-6 API, TML-6 formulations E02, E10, E12, and E13 by oral gavage.

[0078] Dosing Solution Preparation: TML-6 API, E02, E10, E12 and E13 oral formulations were prepared by suspending these TML6 formulated powders in an aqueous vehicle consisting of 0.5% methylcellulose (MC) to a concentration of 2.5 mg / mL TML-6, respectively.

[0079] Plasma sample preparation and bioanalysis Serial blood samples were collected from all animals via the tail vein. Approximately 0.2 mL of blood samples were collected at the following time points: pre-dose and 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours after dosing. Plasma separation was prepared by centrifugation (1,000×g for 15 min at 4° C.) after blood collection. The concentration of TML-6 in rat plasma was determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS) as shown in Figures 6 and 7. The lower limit of quantification (LLOQ) was 0.1 ng / mL. Plasma concentration-time data above the LLOQ at each dose level were used to calculate the PK parameters of TML-6 (Table 7).

[0080] Results: PK studies of TML-6 API and TML-6 formulations E02, E10, E12 and E13 were conducted after oral administration to rats at 25 mg / kg in 0.5% MC suspension. max and AUC (0-∞) The results are summarized in Table 7. There was a significant difference in C between unformulated TML-6 (TML-6 API) and TML-6 formulation E02. maxand AUC (0-∞) There was no significant difference in the C of TML-6. max and AUC (0-∞) The results also showed that formulations with improved dissolution of TML-6 could help improve C max and AUC (0-∞) It was also shown that

[0081] [Table 7]

[0082] The compositions and methods of the present disclosure each have several innovative aspects, no single aspect of which is solely responsible for or required for the desired attributes disclosed herein. The various features and processes described above may be used independently of one another or may be combined in various ways. All possible combinations and subcombinations are intended to be within the scope of the present disclosure. Various modifications to the implementations described in the present disclosure may be readily apparent to those skilled in the art, and the general principles defined herein may be applied to other implementations without departing from the spirit or scope of the present disclosure. Thus, the claims are not intended to be limited to the implementations shown herein, but should be accorded the widest scope consistent with the disclosure, principles, and novel features disclosed herein.

[0083] Certain features described herein in the context of separate implementations may also be implemented in combination in a single implementation. Conversely, various features described in the context of a single implementation may also be implemented in multiple implementations separately or in any suitable subcombination. Furthermore, although features may be described above as acting in a particular combination and may even initially be claimed as such, one or more features from the claimed combination may, in some cases, be deleted from the combination, and the claimed combination may be directed to a subcombination or a variation of the subcombination. No single feature or group of features is necessary or essential to each embodiment.

Claims

1. TML-6 in amorphous form, [Formula 1] or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and one or more excipients.

2. 10. The formulation of claim 1, characterized by a differential scanning calorimetry thermogram that does not contain a sharp endothermic peak.

3. 3. The formulation of claim 1 or 2, characterized by a DSC thermogram that does not contain an endothermic peak corresponding to crystalline TML-6.

4. 4. The formulation of any one of claims 1 to 3, characterized by a DSC thermogram comprising a broad endothermic peak at about 50°C to about 90°C.

5. 10. The formulation of claim 1, characterized by an X-ray powder diffraction (XRPD) pattern that is essentially continuous (without sharp, narrow diffraction peaks).

6. 6. The formulation of claim 5, characterized by an XRPD pattern that does not include degree 2θ-reflections (±0.2° 2θ) at one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°.

7. Approximately 20% (w / w) to 90% (w / w) of TML-6, [chemical 2] or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and from about 10% (w / w) to about 80% (w / w) of one or more excipients.

8. 8. The formulation of claim 7, wherein the TML-6, or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, is in an amorphous form.

9. 9. The formulation of claim 7 or 8, comprising about 70% (w / w) to 90% (w / w) of TML-6, or a pharma- ceutically acceptable salt, solvate, hydrate, or prodrug thereof, and about 10% (w / w) to about 30% (w / w) of one or more excipients.

10. The formulation of any one of claims 7 to 9, wherein the one or more excipients comprises an enteric polymer.

11. 11. The formulation of any one of claims 7 to 10, wherein the one or more excipients comprise at least one of a polymethacrylate-based copolymer, a poly(methacrylic acid)-based copolymer, a poloxamer, and a cellulose derivative excipient.

12. 12. The formulation of claim 11, wherein the ratio of polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer to cellulose derivative excipient ranges from about 1:5 to about 5:

1.

13. 13. The formulation of claim 11 or 12, wherein the amount of polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer ranges from about 10% to about 70% (w / w) and the amount of cellulose derivative excipient ranges from about 10% to about 70% (w / w).

14. Polymethacrylate-based copolymers and / or poly(methacrylic acid)-based copolymers include poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, ethyl acrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:2, polymers of methyl acrylate, methyl methacrylate, and methacrylic acid, poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1, poly(ethyl acrylate, methyl methacrylate) 1:2:1 ... ethyl, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.2, Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.1, Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.1, Poly(ethyl acrylate, methyl methacrylate, 2-trimethyl 14. The formulation of any one of claims 11 to 13, wherein the poly(ethyl acrylate, methyl methacrylate) is selected from the group consisting of ammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate) 2:1 with 0.7% (PEG stearyl ether), poly(ethyl acrylate, methyl methacrylate) 2:1 with 1.5% (nonoxynol), and poly(ethyl acrylate, methyl methacrylate) 2:1 with 1.5% (nonoxynol), and combinations thereof.

15. 15. The formulation of any one of claims 7 to 14, wherein the cellulose derivative excipient is selected from the group consisting of cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, cellulose ester derivatives, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropylmethylcellulose phthalate, microcrystalline cellulose, hydroxyethylcellulose and hydroxypropylmethylcellulose.

16. The formulation according to any one of claims 7 to 25, wherein the formulation is in the form of a tablet, granules, capsule or spray-dried powder.

17. A pharmaceutical composition comprising the formulation of any one of claims 1 to 16 and one or more additional excipients.

18. 18. The pharmaceutical composition of claim 17, wherein the one or more additional excipients include, but are not limited to, diluents, disintegrants, binders, lubricants and glidants.

19. 23. A method for preventing and / or treating a neurodegenerative disease, a liver disease, cancer, a cardiovascular disease, obesity, an inflammatory disease or ageing in a subject in need of such treatment, comprising administering to said subject a formulation according to any one of claims 1 to 21 or a pharmaceutical composition according to claim 17 or 18.

20. 20. The method of claim 19, wherein the neurodegenerative disease is amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease or prion disease.